This article is more than 5 years old. Information may no longer be current.
Rosuvastatin benefited postmenopausal women with dyslipidemia
Click Here to Manage Email Alerts
Postmenopausal women with low-risk dyslipidemia may benefit from rosuvastatin to improve brachial artery pulse wave velocity and carotid stiffness index beta, according to data from a recent study.
Michiya Igase, MD, PhD, and colleagues examined the efficacy of treating dyslipidemia with a statin on three widely used indices of atherosclerosis assessment: carotid intima-media thickness (CIMT); arterial stiffness index beta of the common carotid artery (carotid stiffness beta); and brachial artery pulse wave velocity (baPWV).
Postmenopausal women aged at least 55 years with dyslipidemia were included in the study (n=51) and were randomly assigned to 2.5 mg rosuvastatin or no statin.
After 3 and 12 months, patients in the treatment arm experienced improved carotid stiffness beta and baPWV compared with controls. Additionally, CIMT was significantly lower in the treatment group at 12 months vs. controls. The researchers also reported significant decreases in LDL cholesterol.
“Interestingly, changes in CIMT during the 12-month period were significantly correlated with changes in high-sensitivity C-reactive protein during the 3-month period independently of lipid profile,” they wrote.
The researchers added that additional studies should clarify the common mechanisms underlying the link between cholesterol-lowering treatment and atherosclerosis in this patient population.
Click Here to Manage Email Alerts